Therapeutic Classification: antirheumatics
Pharmacologic Classification: cox 2 inhibitors
Absorption: Bioavailability unknown.
Distribution: Extensively distributed to tissues.
Protein Binding: 97%.
Metabolism/Excretion: Mostly metabolized by the liver via the CYP2C9 isoenzyme; the CYP2C9 isoenzyme exhibits genetic polymorphism; poor metabolizers may have significantly ↑ celecoxib concentrations and an ↑ risk of adverse effects; <3% excreted unchanged in urine and feces.
Half-Life: 11 hr.
Osteoarthritis
- PO (Adults ): 200 mg once daily or 100 mg twice daily. CYP2C9 poor metabolizers:↓ dose by 50%.
Hepatic Impairment
- PO (Adults ): Moderate hepatic impairment:↓ dose by 50%.
Rheumatoid Arthritis
- PO (Adults ): 100–200 mg twice daily (capsules). CYP2C9 poor metabolizers:↓ dose by 50%.
Hepatic Impairment
- PO (Adults ): Moderate hepatic impairment:↓ dose by 50%.
Ankylosing Spondylitis
- PO (Adults ): 200 mg once daily (capsules) or 100 mg twice daily (capsules); may ↑ dose after 6 wk to 400 mg/day. CYP2C9 poor metabolizers:↓ dose by 50%.
Hepatic Impairment
- PO (Adults ): Moderate hepatic impairment:↓ dose by 50%.
Juvenile Rheumatoid Arthritis
- PO (Children ≥2 yr, 10–25 kg): 50 mg twice daily (capsules).
- PO (Children ≥2 yr, ≥25 kg): 100 mg twice daily (capsules).
Hepatic Impairment
- PO (Children ≥2 yr): Moderate hepatic impairment:↓ dose by 50%.
Acute Pain or Primary Dysmenorrhea
- PO (Adults ): 400 mg initially, then a 200-mg dose if needed on the first day; then 200 mg twice daily as needed (capsules). CYP2C9 poor metabolizers:↓ dose by 50%.
Hepatic Impairment
- PO (Adults ): Moderate hepatic impairment:↓ dose by 50%.
Acute Treatment of Migraine
- PO (Adults ): 120 mg as a single dose (not to exceed 120 mg/24 hr). CYP2C9 poor metabolizers: 60 mg as a single dose (not to exceed 60 mg/24 hr).
Hepatic Impairment
- PO (Adults ): Moderate hepatic impairment: 60 mg as a single dose (not to exceed 60 mg/24 hr).
